In literature it is estimated that only 20% of prostatic carcinoma are clinically important and indicators of biological aggressiveness of the neoplasm would therefore seem necessary. We considered 44 radical prostatectomies that were performed in our Division between 1989 and 1996. A histological section was selected for each patient on which the expression of C-erb B2 and p53 were tested with immunohistochemical methods. In these patients, who were homogeneous as far as surgical criteria are concerned, no subgroups with different progression were found.
RossJ.S., NazeerT., ChurchK., AmatoC., FiggeH., RifkinM.D., FisherH.A.G.: Contribution of Her-2/neu oncogene expression to tumour grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer, 72: 3020–8, 1993.
4.
ScardinoP.T., WeaverR., HudsonM.A.: Early detection of prostate cancer. Hum. Pathol., 23: 211–222, 1992.
5.
SchmidH.P., McNealJ.E.: An abbreviated standard procedure for accurate tumour volume estimation in prostate cancer. Am. J. Surg. Pathol., 16 (2): 184–191, 1992.
6.
VisakorpiT., KallioniemiO.P., HeikkinenA., KoivulaT., IsolaJ.: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84: 883–887, 1992.
AprikianA.G., SarkisA.S., FairW.R., ZhangZ., FuksZ., Cordon-CardoC.: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151: 1276–1280, 1994.
9.
SadasivanR., MorganR., JenningsS., AustenfeldM., Van Veldhuizen StephensR., NobleM.: Overexpression of Her-2/neu may be an indication of poor prognosis in prostate cancer. J. Urol., 150: 126–131, 1993.
